Literature DB >> 32275498

Severe Acute Respiratory Syndrome Coronavirus 2 Infection among Returnees to Japan from Wuhan, China, 2020.

Yuzo Arima, Tomoe Shimada, Motoi Suzuki, Tadaki Suzuki, Yusuke Kobayashi, Yuuki Tsuchihashi, Haruna Nakamura, Kaoru Matsumoto, Asuka Takeda, Keisuke Kadokura, Tetsuro Sato, Yuichiro Yahata, Noriko Nakajima, Minoru Tobiume, Ikuyo Takayama, Tsutomu Kageyama, Shinji Saito, Naganori Nao, Tamano Matsui, Tomimasa Sunagawa, Hideki Hasegawa, Makoto Ohnishi, Takaji Wakita.   

Abstract

In early 2020, Japan repatriated 566 nationals from China. Universal laboratory testing and 14-day monitoring of returnees detected 12 cases of severe acute respiratory syndrome coronavirus 2 infection; initial screening results were negative for 5. Common outcomes were remaining asymptomatic (n = 4) and pneumonia (n = 6). Overall, screening performed poorly.

Entities:  

Keywords:  2019 novel coronavirus disease; Asymptomatic infections; COVID-19; SARS-CoV-2; bias; coronavirus disease; pneumonia; prevalence; quarantine; respiratory infections; severe acute respiratory syndrome coronavirus 2; viruses; zoonoses

Mesh:

Year:  2020        PMID: 32275498      PMCID: PMC7323539          DOI: 10.3201/eid2607.200994

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


With the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Wuhan, China, several countries, including Japan, repatriated their nationals (–). During January 29–31, 2020, a total of 566 Japanese nationals were repatriated via 3 chartered flights from Wuhan (206, 210, and 150 passengers). After passengers disembarked in Tokyo, Japan, quarantine officials assessed them for signs/symptoms (e.g., fever, respiratory illness) of coronavirus disease (COVID-19) (). A total of 28 symptomatic passengers were transferred to select hospitals for isolation. The remaining 538 were transported to a designated hospital, where another 35 were found to be symptomatic and were hospitalized there or transferred to other hospitals, leaving 503 asymptomatic persons for observation in quarantine (Figure).
Figure

Results of testing 566 Japanese returnees from Wuhan, China, for severe acute respiratory syndrome coronavirus 2 by real-time reverse transcription PCR, January–February 2020. *Two persons were sampled on day 3, when they provided informed consent.

Results of testing 566 Japanese returnees from Wuhan, China, for severe acute respiratory syndrome coronavirus 2 by real-time reverse transcription PCR, January–February 2020. *Two persons were sampled on day 3, when they provided informed consent.

The Study

We conducted day 1 entry screening by testing oropharyngeal swab samples collected from all 566 returnees at the hospitals to which they were initially transported for SARS-CoV-2 (); all tests were based on the real-time reverse transcription PCR developed by the National Institute of Infectious Diseases (). Hospitalized patients in isolation and asymptomatic returnees in quarantine were monitored daily for 14 days. If any signs/symptoms developed in a quarantined person, that person was transported to a designated hospital and oropharyngeal swab samples were collected for testing. We conducted exit screening for quarantined persons who remained illness-free by collecting oropharyngeal swab samples on day 14. The National Institute of Infectious Diseases Ethics Committee approved the study (registration no. 1096), and all 566 returnees who provided specimens gave written informed consent. Among the 63 passengers who were symptomatic at entry screening, 2 (3.2%) were positive by PCR (Figure); test results were subsequently positive for 2 more. For 1 of these patients, pneumonia was diagnosed on day 1 and a sputum sample was positive on day 3; the other patient had fever and cough on day 1, pneumonia diagnosed on day 2, and a positive oropharyngeal swab sample on day 6. Excluding 1 patient who remained hospitalized for stroke, the remaining 58 patients were transferred to designated quarantine facilities after confirmation of good health and negative PCR results; all 58 remained asymptomatic after discharge, and PCR results were negative at exit screening. For the 503 asymptomatic/subclinical passengers, entry-screening PCR results were positive for 5 (1.0%) (Figure); 3 remained asymptomatic, but mild signs/symptoms (fever, headache, sore throat) developed for 2 persons (1 on day 2, 1 on day 4). Of the remaining 498 persons with negative PCR results, 484 were quarantined at designated facilities and 14 at home. During quarantine, fever developed in 1 facility-quarantined and 1 home-quarantined person on day 10; both were confirmed positive by PCR, and pneumonia subsequently developed in both. The facility-quarantined case-patient was in a single room; no other person from this facility acquired COVID-19 or had a positive test result at exit screening. One person who remained asymptomatic had a positive test result at exit screening. Exit-screening results are pending for the patient hospitalized for stroke and the remaining 13 home-quarantined persons. Among the 566 returnees, 12 cases of SARS-CoV-2 infection were detected; 540/541 facility-quarantined persons were confirmed negative by PCR performed on days 1 and 14 (197/197, 199/199, and 144/145 for the 3 flights). Entry screening detected 7 infections, for an infection point prevalence of 1.2%; infection period prevalence was 2.2% (12/552 returnees with complete follow-up). Despite universal testing, entry screening captured only 7/12 cases (58.3% sensitivity). Although screening symptomatic passengers (3.2%) was more efficient than screening all passengers (1.2%), screening only symptomatic passengers missed 5/7 prevalent infections at entry. Among symptomatic passengers, with 2 initially negative persons subsequently testing positive, entry-screening sensitivity was 2/4 (50%). Among asymptomatic passengers, with 3 initially negative persons subsequently testing positive, entry-screening sensitivity was 5/8 (62.5%).

Conclusions

Testing all returnees—with follow-up for disease onset and course—enabled us to evaluate the spectrum of severity for SARS-CoV-2 infections (Table). From least to most severe, 4 patients experienced asymptomatic infection, 2 mild illness, and 6 pneumonia. Prospective monitoring proved essential because of the 7 prevalent infections at entry, 5 were asymptomatic, 1 mild, and 1 pneumonia. Even with potential underascertainment of asymptomatic cases because of a lack of serologic assessment (,) (i.e., interval-censoring during screening tests), it is noteworthy that 4/12 persons with infections were asymptomatic. Although numbers are small, severity seemed to be age dependent (Table). No infections were detected among the 100 persons <30 years of age; of the 2 infections detected among the 138 persons 30–39 years of age, both persons were asymptomatic. Although no person in this study died, only 1 was >69 years of age. Regarding sex, excluding 1 returnee for whom sex was unknown and 14 for whom exit-screening results are pending, of the remaining 551 returnees, 9 (1.8%) of the 506 male passengers (2 asymptomatic, 2 mild, 5 pneumonia) and 3 (6.7%) of the 45 female passengers (2 asymptomatic, 1 pneumonia) were infected.
Table

Distribution of severe acute respiratory syndrome coronoavirus 2 infections and clinical outcomes, by age group, among 566 Japanese returnees from Wuhan, China, January–February 2020

Age group, yNo. returnees*No. (%) infected†Outcome
No. asymptomaticNo. with mild illnessNo. with pneumoniaNo. deaths
<10600000
10–1940 0000
20–29900 0000
30–391382 (1.4)2000
40–491684 (2.4)0130
50–591195 (4.2)1130
60–69261 (3.8)1000
70–7910 0000

*Day-14 exit-screening test results pending for 14 persons. 
†Testing by reverse transcription PCR.

*Day-14 exit-screening test results pending for 14 persons. 
†Testing by reverse transcription PCR. Our findings have public health implications. As recently reported (), we found that symptom-based screening performed poorly, missing asymptomatic and presymptomatic cases. Even with universal screening, nearly half of cases were missed. Because an asymptomatic case was detected at exit screening, limiting testing of quarantined persons to those with signs/symptoms would have missed such a case; with exit-screening results pending for 14 returnees, sensitivity could be lower. The poor sensitivity of single-point testing highlights the challenges of detecting SARS-CoV-2 infections. The potentially long incubation period of COVID-19 was consistent with that recently reported (,) and contributed to the large proportion of missed cases. Active daily monitoring ensured that specific illness-onset times were captured, protected from the limitations associated with patient recall of symptom onset (). Although exposure to SARS-CoV-2 occurred at some time before quarantine (i.e., left-censored), our setting enabled us to estimate the minimum incubation period for each incident symptomatic case by taking the return date as the exposure time. Determining the specific exposure time can be difficult and is conditional according to the definition of contact. Given such qualifications, a conservative minimum incubation period of 10 days obtained prospectively in a clean quarantine setting, without recall or assumptions regarding transmission modes, is noteworthy. Testing and follow-up of all returnees provided valuable information about the spectrum of SARS-CoV-2 infection. Most reported data have been from medically attended patients, skewed toward symptomatic patients and more severe cases, limiting our knowledge of the clinical spectrum of infection (,). In our setting, we could remove the influence of patients’ health-seeking behaviors and clinicians’ diagnostic practices and found that 4/12 case-patients were asymptomatic. At the same time, of the 8 case-patients who experienced symptoms, pneumonia developed in 6. Our findings were also consistent with the reported age-dependent nature of COVID-19 (,–); infection and clinical attack rates were lower among younger persons. Shedding light on the severity pyramid among those infected—not only among those who sought care—provides an evidence base for risk communication, healthcare planning, and public health response. Combined with reports suggesting transmissibility of SARS-CoV-2 from asymptomatic/subclinical case-patients (,,,), our findings suggest that controlling COVID-19 through the usual tools of syndrome-based surveillance and contact tracing alone may be difficult. When confronted with an emerging pathogen, researchers can generate critical epidemiologic information by studying quarantine populations. As with the First Few X study (), our design is protected from the usual biases of passively reported surveillance data. Aggregating high-quality data from these types of investigations can build a larger severity pyramid, enabling reliable estimation of various severity measures (e.g., symptomatic proportion of infected case-patients, case severity proportion among those who are symptomatic). We recommend using similar assessments to help elucidate the epidemiology of SARS-CoV-2 and inform public health response.
  14 in total

1.  Development of Genetic Diagnostic Methods for Detection for Novel Coronavirus 2019(nCoV-2019) in Japan.

Authors:  Kazuya Shirato; Naganori Nao; Harutaka Katano; Ikuyo Takayama; Shinji Saito; Fumihiro Kato; Hiroshi Katoh; Masafumi Sakata; Yuichiro Nakatsu; Yoshio Mori; Tsutomu Kageyama; Shutoku Matsuyama; Makoto Takeda
Journal:  Jpn J Infect Dis       Date:  2020-02-18       Impact factor: 1.362

2.  Defining the Epidemiology of Covid-19 - Studies Needed.

Authors:  Marc Lipsitch; David L Swerdlow; Lyn Finelli
Journal:  N Engl J Med       Date:  2020-02-19       Impact factor: 91.245

3.  A Novel Coronavirus Emerging in China - Key Questions for Impact Assessment.

Authors:  Vincent J Munster; Marion Koopmans; Neeltje van Doremalen; Debby van Riel; Emmie de Wit
Journal:  N Engl J Med       Date:  2020-01-24       Impact factor: 91.245

4.  Escaping Pandora's Box - Another Novel Coronavirus.

Authors:  David M Morens; Peter Daszak; Jeffery K Taubenberger
Journal:  N Engl J Med       Date:  2020-02-26       Impact factor: 91.245

5.  Update: Public Health Response to the Coronavirus Disease 2019 Outbreak - United States, February 24, 2020.

Authors:  Daniel B Jernigan
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2020-02-28       Impact factor: 17.586

6.  Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany.

Authors:  Camilla Rothe; Mirjam Schunk; Peter Sothmann; Gisela Bretzel; Guenter Froeschl; Claudia Wallrauch; Thorbjörn Zimmer; Verena Thiel; Christian Janke; Wolfgang Guggemos; Michael Seilmaier; Christian Drosten; Patrick Vollmar; Katrin Zwirglmaier; Sabine Zange; Roman Wölfel; Michael Hoelscher
Journal:  N Engl J Med       Date:  2020-01-30       Impact factor: 91.245

7.  SARS-CoV-2 Infection among Travelers Returning from Wuhan, China.

Authors:  Oon-Tek Ng; Kalisvar Marimuthu; Po-Ying Chia; Vanessa Koh; Calvin J Chiew; Liang De Wang; Barnaby E Young; Monica Chan; Shawn Vasoo; Li-Min Ling; David C Lye; Kai-Qian Kam; Koh-Cheng Thoon; Lalitha Kurupatham; Zubaidah Said; Ethan Goh; Constance Low; Soon-Kok Lim; Pream Raj; Olivia Oh; Valerie T J Koh; Cuiqin Poh; Tze-Minn Mak; Lin Cui; Alex R Cook; Raymond T P Lin; Yee-Sin Leo; Vernon J M Lee
Journal:  N Engl J Med       Date:  2020-03-12       Impact factor: 91.245

8.  Clinical Characteristics of Coronavirus Disease 2019 in China.

Authors:  Wei-Jie Guan; Zheng-Yi Ni; Yu Hu; Wen-Hua Liang; Chun-Quan Ou; Jian-Xing He; Lei Liu; Hong Shan; Chun-Liang Lei; David S C Hui; Bin Du; Lan-Juan Li; Guang Zeng; Kwok-Yung Yuen; Ru-Chong Chen; Chun-Li Tang; Tao Wang; Ping-Yan Chen; Jie Xiang; Shi-Yue Li; Jin-Lin Wang; Zi-Jing Liang; Yi-Xiang Peng; Li Wei; Yong Liu; Ya-Hua Hu; Peng Peng; Jian-Ming Wang; Ji-Yang Liu; Zhong Chen; Gang Li; Zhi-Jian Zheng; Shao-Qin Qiu; Jie Luo; Chang-Jiang Ye; Shao-Yong Zhu; Nan-Shan Zhong
Journal:  N Engl J Med       Date:  2020-02-28       Impact factor: 91.245

9.  Evidence of SARS-CoV-2 Infection in Returning Travelers from Wuhan, China.

Authors:  Sebastian Hoehl; Holger Rabenau; Annemarie Berger; Marhild Kortenbusch; Jindrich Cinatl; Denisa Bojkova; Pia Behrens; Boris Böddinghaus; Udo Götsch; Frank Naujoks; Peter Neumann; Joscha Schork; Petra Tiarks-Jungk; Antoni Walczok; Markus Eickmann; Maria J G T Vehreschild; Gerrit Kann; Timo Wolf; René Gottschalk; Sandra Ciesek
Journal:  N Engl J Med       Date:  2020-02-18       Impact factor: 91.245

10.  Incubation period of 2019 novel coronavirus (2019-nCoV) infections among travellers from Wuhan, China, 20-28 January 2020.

Authors:  Jantien A Backer; Don Klinkenberg; Jacco Wallinga
Journal:  Euro Surveill       Date:  2020-02
View more
  13 in total

1.  Clinical Characteristics and Risk Factors for Severe Outcomes of Novel Coronavirus Infection, January-March 2020, Japan.

Authors:  Yuuki Tsuchihashi; Yuzo Arima; Takuri Takahashi; Kazuhiko Kanou; Yusuke Kobayashi; Tomimasa Sunagawa; Motoi Suzuki
Journal:  J Epidemiol       Date:  2021-06-22       Impact factor: 3.211

2.  Quarantine alone or in combination with other public health measures to control COVID-19: a rapid review.

Authors:  Barbara Nussbaumer-Streit; Verena Mayr; Andreea Iulia Dobrescu; Andrea Chapman; Emma Persad; Irma Klerings; Gernot Wagner; Uwe Siebert; Dominic Ledinger; Casey Zachariah; Gerald Gartlehner
Journal:  Cochrane Database Syst Rev       Date:  2020-09-15

3.  International travel-related control measures to contain the COVID-19 pandemic: a rapid review.

Authors:  Jacob Burns; Ani Movsisyan; Jan M Stratil; Renke Lars Biallas; Michaela Coenen; Karl Mf Emmert-Fees; Karin Geffert; Sabine Hoffmann; Olaf Horstick; Michael Laxy; Carmen Klinger; Suzie Kratzer; Tim Litwin; Susan Norris; Lisa M Pfadenhauer; Peter von Philipsborn; Kerstin Sell; Julia Stadelmaier; Ben Verboom; Stephan Voss; Katharina Wabnitz; Eva Rehfuess
Journal:  Cochrane Database Syst Rev       Date:  2021-03-25

4.  High Probability of Long Diagnostic Delay in Coronavirus Disease 2019 Cases with Unknown Transmission Route in Japan.

Authors:  Tsuyoshi Ogata; Hideo Tanaka
Journal:  Int J Environ Res Public Health       Date:  2020-11-21       Impact factor: 3.390

5.  Travel-related control measures to contain the COVID-19 pandemic: an evidence map.

Authors:  Ani Movsisyan; Jacob Burns; Renke Biallas; Michaela Coenen; Karin Geffert; Olaf Horstick; Irma Klerings; Lisa Maria Pfadenhauer; Peter von Philipsborn; Kerstin Sell; Brigitte Strahwald; Jan M Stratil; Stephan Voss; Eva Rehfuess
Journal:  BMJ Open       Date:  2021-04-09       Impact factor: 2.692

6.  Comparison of infection control strategies to reduce COVID-19 outbreaks in homeless shelters in the United States: a simulation study.

Authors:  Lloyd A C Chapman; Margot Kushel; Sarah N Cox; Ashley Scarborough; Caroline Cawley; Trang Q Nguyen; Isabel Rodriguez-Barraquer; Bryan Greenhouse; Elizabeth Imbert; Nathan C Lo
Journal:  BMC Med       Date:  2021-05-07       Impact factor: 8.775

7.  Lessons Learned from Japan's Response to the First Wave of COVID-19: A Content Analysis.

Authors:  Kazuki Shimizu; Masashi Negita
Journal:  Healthcare (Basel)       Date:  2020-10-23

8.  Proportion of asymptomatic infection among COVID-19 positive persons and their transmission potential: A systematic review and meta-analysis.

Authors:  Mercedes Yanes-Lane; Nicholas Winters; Federica Fregonese; Mayara Bastos; Sara Perlman-Arrow; Jonathon R Campbell; Dick Menzies
Journal:  PLoS One       Date:  2020-11-03       Impact factor: 3.240

9.  Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: A living systematic review and meta-analysis.

Authors:  Diana Buitrago-Garcia; Dianne Egli-Gany; Michel J Counotte; Stefanie Hossmann; Hira Imeri; Aziz Mert Ipekci; Georgia Salanti; Nicola Low
Journal:  PLoS Med       Date:  2020-09-22       Impact factor: 11.069

Review 10.  Features of enteric disease from human coronaviruses: Implications for COVID-19.

Authors:  Nevio Cimolai
Journal:  J Med Virol       Date:  2020-06-05       Impact factor: 20.693

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.